John Christopher Jison

BN2_J

March 10, 2010

USLS

Drug Study
Generic Name Dosage and Route of Administration
Arthritis Adult: 2.6-5.2 g/day in divided doses q4-q6h Child: 90-130 mg/kg/day in divided doses q4-q6 dses q4h

Mechanism of Action

Indication

Contraindication

Adverse Effects

Nursing Consideration

Aspirin (aspir-in) acetylsalicylic acid

Blocks pain impulses in CNS, inhibition of prostaglandin Brand Name: synthesis; Arthrinol, Arthrisin, antipyretic Aspergum Bayer Pain/Fever action results Aspirin, Coryphen, Adult: 325-650 mgq4h prn, from Easpirin, Ecotrin, not 4g/day vasodilation of Empirin, Entrophen Child: 40-100 mg/kg/day in peripheral divided doses q4-6h prn vessels; Classifications: decreases Nonnarcotic Kawasaki Disease platelet analgesic, Child: 80-120 mg/kg/day in 4 aggregation. nonsteroidal anti- divided doses inflammatory, antipyretic, Throomboembolic Disorders: antiplatelet Adult: 325-650 mg/day or bid

Mild to moderate pain or fever including rheumatoid arthritis, osteoarthritis, thromboembol ic disorders; transient ischemic attacks, rheumatic fever, postmyocardia l infarction, prophylaxis of MI, ischemic stroke, angina

Hypersensitivity to salicylates tatrazin, GI bleeding, bleeding disorders, chidren<12 yr, children with flulike symptoms, Pregnancy (3rd Trimester), lactation, vit K deficiency, peptic ulcer

*HEMA: Thrombocytopenia, aggranulocytosis, leukopenia, neutropenia, hemolytic anemia *CNS: Stimulation, drowsiness, dizziness, confusion, convulsion, flushing, hallucinations, coma *GI: Nausea and vomiting, *GI bleeding, diarrhea, heartburn, anorexia, hepatitis *INTEG: Rash, urticuria, bruising *EENT: Tinnitus, hearing loss *CV: Rapid pulse, pulmonary edema *RESP: Wheezing, hypernea *ENDO: Hypoglycemia, hyponatremia, hypokalemia *SYST: Reyes Syndrome

*Liver function studies: AST, ALT, bilirubin, creatinine if patient is on long term therapy *Renal function studies: BUN, urine creatinine if patient is on long term therapy *Blood Studies: CBC, Hct, Hgb, pro-time if patient is on long term therapy *I&O ratio: decreasing output may indicate renal failure *Hepatotoxicity: dark urine, clay-colored stools, yellowing of skin, sclera, itching, abdominal pain, fever and diarrhea *Visual changes: blurring, halos; corneal, retinal damage Edema in feet, ankles and legs